Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients

American Journal of Transplantation

Volumn 6, Issue 5 I, 2006, Pages 986-992

  Kuppahally, S ^a   Al Khaldi, A ^a   Weisshaar, D ^a   Valantine, H A ^a   Oyer, P ^a   Robbins, R C ^a   Hunt, S A ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Effusion; Mycophenolate mofetil; Pericardial; Pleural; Sirolimus; Wound healing

Indexed keywords

COTRIMOXAZOLE; CYCLOSPORIN; DACLIZUMAB; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; DRUG DERIVATIVE; MYCOPHENOLIC ACID;

ABDOMINAL PAIN; ADULT; ARTICLE; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; EXTRACORPOREAL CIRCULATION; FEMALE; GRAFT RECIPIENT; HEADACHE; HEART GRAFT; HUMAN; HYPERPLASIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PLEURA EFFUSION; PRIORITY JOURNAL; SEIZURE; SURGICAL RISK; SURGICAL WOUND; VASCULAR DISEASE; WOUND HEALING; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HEART TRANSPLANTATION; IMMUNOLOGY; INJURY; MIDDLE AGED; POSTOPERATIVE COMPLICATION; RACE; RETROSPECTIVE STUDY;

CONTINENTAL POPULATION GROUPS; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SIROLIMUS; WOUND HEALING; WOUNDS AND INJURIES;

EID: 33745288559     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01282.x     Document Type: Article

References (19)

1. Dean PG, Lund WJ, Larson TS et al. Wound-healing complications after kidney transplantation: A prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004; 77: 1555-1561.
2. Dunkelberg JC, Trotter JF, Wachs M et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl 2003; 9: 463-468.
3. Groetzner J, Kur F, Spelsberg F et al. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J Heart Lung Transplant 2004; 23: 632-638.
4. Keogh A, Richardson M, Ruygrok P et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: A randomized clinical trial. Circulation 2004; 110: 2694-2700.
5. Montalbano M, Neff GW, Yamashiki N et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: An analysis of sirolimus-related complications. Transplantation 2004; 78: 264-268.
6. Guilbeau JM. Delayed wound healing with sirolimus after liver transplant. Ann Pharmacother 2002; 36: 1391-1395.
7. Fishbein TM, Florman S, Gondolesi G et al. Intestinal transplantation before and after the introduction of sirolimus. Transplantation 2002; 73: 1538-1542.
8. Valente JF, Hricik D, Weigel K et al. Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 2003; 3: 1128-1134.
9. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194-202.
10. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271-280.
11. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-858.
12. Radovancevic B, El-Sabrout R, Thomas C, Radovancevic R, Frazier OH, Van Buren C. Rapamycin reduces rejection in heart transplant recipients. Transplant Proc 2001; 33: 3221-3222.
13. Snell GI, Levvey BJ, Chin W et al. Rescue therapy: A role for sirolimus in lung and heart transplant recipients. Transplant Proc 2001; 33: 1084-1085.
14. Meiser B, Reichart B, Adamidis I, Uberfuhr P, Kaczmarek I. First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation. Am J Transplant 2005; 5: 827-831.
15. Cao W, Mohacsi P, Shorthouse R, Pratt R, Morris RE. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation 1995; 59: 390-395.
16. King-Biggs MB, Dunitz JM, Park SJ, Kay Savik S, Hertz MI. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 2003; 75: 1437-1443.
17. Troppmann C, Pierce JL, Gandhi MM, Gallay BJ, McVicar JP, Perez RV. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: A matched-pair pilot study. Transplantation 2003; 76: 426-429.
18. Quin JA, Tauriainen MP, Huber LM et al. Predictors of pericardial effusion after orthotopic heart transplantation. J Thorac Cardiovasc Surg 2002; 124: 979-983.
19. Lenner R, Padilla ML, Teirstein AS, Gass A, Schilero GJ. Pulmonary complications in cardiac transplant recipients. Chest 2001; 120: 508-513.